Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

2,172

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2025

Conditions
Breast Cancer
Interventions
DRUG

Docetaxel

Docetaxel chemotherapy (injection)

DRUG

Cyclophosphamide

Cyclophosphamide chemotherapy (injection)

Trial Locations (14)

110001

RECRUITING

The First Hospital of China Medical University, Shenyang

116027

RECRUITING

The Second Hospital of Dalian Medical University, Dalian

130021

RECRUITING

The First Bethune Hospital of Jilin University (The First Hospital of Jilin University), Changchun

150081

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

200011

RECRUITING

OB/GYN Hospital of Fudan University, Shanghai

200032

RECRUITING

Fudan University Shanghai Cancer Hospital, Shanghai

266000

RECRUITING

The Affiliated Hospital of Qingdao University, Qingdao

300052

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310003

RECRUITING

The First Affiliated Hospital, ZheJiang University, Hangzhou

310009

RECRUITING

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hanzhou

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

350001

RECRUITING

Fujian Medical University Union Hospital, Fuzhou

400030

RECRUITING

Chongqing Cancer Hospital, Chongqing

510120

RECRUITING

Sun Yet-Sen Memorial Hospital, Sun Yet-Sen University, Guangzhou

All Listed Sponsors
lead

Fudan University

OTHER

NCT03926091 - Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer | Biotech Hunter | Biotech Hunter